Many genetic diseases lack effective treatments, leaving patients with limited options to manage their conditions. Current approaches often fail to address the underlying genetic cause, offering only symptomatic relief. Neurological, lung, and liver disorders, in particular, present significant challenges for traditional therapeutic interventions.

This company develops gene therapies that utilize a single vector to both silence and replace damaged genes, offering a potential curative approach for patients with genetic diseases. The platform targets the root cause of the disease by correcting the faulty genetic code. By addressing the underlying genetic defect, the therapy aims to provide long-term benefits and potentially eliminate the need for ongoing treatments. The initial focus is on neurological, lung, and liver disorders, where the platform's unique capabilities can offer a significant advantage over existing therapies.

Single-vector gene therapy platform for simultaneous gene silencing and replacement.

Targeted delivery to affected tissues in neurological, lung, and liver disorders.

Proprietary vector design for efficient gene transfer and expression.

Potential for long-term therapeutic effect with a single administration.

The primary target audience includes patients diagnosed with specific genetic diseases affecting the neurological system, lungs, or liver, as well as their families and healthcare providers.